Interpace Biosciences, Inc. (IDXG) |
|
2.57 -0.03 (-1.15%)
|
05-31 10:23 |
|
Open: |
2.73 |
Pre. Close: |
2.6 |
|
High:
|
2.73 |
Low:
|
2.57 |
|
Volume:
|
1,700 |
Market Cap:
|
11(M) |
|
|
|
Technical analysis |
as of: |
|
Overall:
|
 |
| |
| Target: |
Six months: One year: |
| Support: |
Support1: Support2: |
| Resistance: |
Resistance1: Resistance2: |
| Pivot: |
|
| Moving Average: |
MA(5): MA(20):
MA(100): MA(250): |
| MACD: |
MACD(12,26): Signal(9): |
| Stochastic oscillator: |
%K(14,3): %D(3): |
| RSI: |
RSI(14): |
| 52-week: |
High: Low: |
| Average Vol(K): |
3-Month: 0 (K) 10-Days: 0 (K) |
|
Price, moving averages and Bollinger Bands |
|
|
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
- |
- |
|
Low:
|
- |
- |
|
Close:
|
- |
- |
|
Company Description |
|
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. |
Headline News |
Fri, 12 May 2023
Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results - Yahoo Finance
Mon, 27 Mar 2023
Interpace Biosciences Announces Full Year and Fourth Quarter ... - GlobeNewswire
Wed, 31 Aug 2022
Interpace Biosciences Completes Sale of Its Pharma Services ... - GlobeNewswire
Wed, 11 May 2022
Miroculus to Optimize Automated Next Generation Sequencing ... - GlobeNewswire
Mon, 21 Feb 2022
Insider Weekends: Peter Kamin Purchases Shares Of IAA (NYSE:IAA) - Seeking Alpha
Mon, 03 May 2021
Interpace Biosciences Announces Improved Coverage for ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: PNK |
| Sector: Healthcare |
| Industry: Diagnostics & Research |
| Shares Out. |
0 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
(%) |
|
% Held by Institutions
|
(%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
|
|
EPS Est Next Qtl
|
|
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
|
|
Profit Margin (%)
|
|
|
Operating Margin (%)
|
|
|
Return on Assets (ttm)
|
|
|
Return on Equity (ttm)
|
|
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
|
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
|
|
PEG Ratio
|
|
|
Price to Book value
|
|
|
Price to Sales
|
|
|
Price to Cash Flow
|
|
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
|
|
Ex-Dividend Date
|
|
|
Your Ad Here
|
|
